Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation
Nextleaf Solutions Ltd.

A pioneering force in the cannabis industry, driving innovation in extraction and life science technology.

 

Bullboard - Investor Discussion Forum Nextleaf Solutions Ltd C.OILS

Alternate Symbol(s):  OILFF

Nextleaf Solutions Ltd. is a cannabis processor with a portfolio of federally regulated emerging consumer brands, market validated cannabis derivative products, and high-potency bulk ingredients. The Company’s multi-patented, highly automated, closed loop extraction, and distillation technology sets the global standard for processing cannabis at scale. The Company manufactures over 80 different... see more

CSE:OILS - Post Discussion

View:
Post by Dude51 on Dec 01, 2023 3:19pm

Anyday...

Tik tok

"Under the Medical Marijuana and Cannabidiol Research Expansion Act—which is generally designed to streamline the process of accessing marijuana and its components for study purposes—HHS is required to send the report to certain congressional committees within one year of Biden signing the bill, a deadline that arrives on Saturday."

That sounds like tomorrow?


https://www.marijuanamoment.net/top-federal-health-agency-owes-congress-a-report-on-marijuanas-medical-uses-and-research-barriers-as-another-agency-misses-cannabis-deadline/

GL
Comment by signreader on Dec 01, 2023 7:14pm
For the long suffering sharehlders of this company it is hard not to imagine we are flogging a dead horse. Despite all the exuberance and new developments the price languishes on like it is on life support...It is just plain pathertic at 5 cents. Hopefully management will take note and do the necessary to elevate the sp.
Comment by AuroraAurora on Dec 02, 2023 2:11am
Do we know when financials are being released. It's sure been a long road. Hopefully the team is incredibly hard at work in the background and we get some good news soon versus just waiting for financials after financials without any SP appreciation. 
Comment by signreader on Dec 03, 2023 4:29am
Hopefully the coming financials will show an improved performance of the company by way of better margins and earnings as they appear to be the only way to uplift the sp. As far as I recall exciting announcements by the ocmpany soon fizzles out into a big yawn, resulting in even lower sp. I dread to think what would have happened to the company had they not expanded into the retail and ...more  
Comment by Dynaboy72 on Dec 04, 2023 9:11am
Maybe if you so concerned about what the company's  doing maybe go to the shareholder meeting instead of crying  about it.nextleaf will bring a good returns  but patience is the key.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with C.OILS


Investor Presentation

View the Presentation

Investment Opportunity

  • Market Leadership with patented extraction and distillation technology offering significant efficiencies and higher purity levels over competing technologies
     
  • Debt free and four consecutive years of positive gross revenue. Reported fiscal YE 2023 gross revenue of $9.96MM with a gross profit of $2.3MM
     
  • Untapped domestic growth across various market segments, and the ability to scale production without additional capital expenditure
     
  • Backed by 19 U.S. patents and over 75 global patents provides a solid foundation for future growth and potential licensing opportunities

Nextleaf Solutions Ltd. With CEO, Emma Andrews

Primary Extraction

Distillation

Manufacturing: Softgels

The Vault

Facebook